Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.44 |
| ▸ | FPR2 | P25090 | 3/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.38 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23810852 | 0.89 | NTSR1 (0.51) | HTR7FPR2NTSR1HDAC6 | |
| SCHEMBL25338684 | 0.87 | HTR7 (0.48) | HTR7MCL1FGFR1FGFR4 | |
| SCHEMBL5023905 | 0.85 | MCL1 (0.41) | MCL1HDAC6KDM4EALDH1A1POLB | |
| SCHEMBL21810438 | 0.85 | KDM4E (0.48) | HTR7NTSR1HDAC6KDM4EALDH1A1 | |
| SCHEMBL3057043 | 0.84 | MCL1 (0.41) | MCL1NTSR1HDAC6KDM4EALDH1A1 | |
| SCHEMBL5015441 | 0.80 | MCL1 (0.43) | MCL1HDAC6KDM4EALDH1A1 | |
| SCHEMBL30229742 | 0.80 | KMT2A (0.59) | NTSR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3597779 | 0.80 | KMT2A (0.59) | NTSR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3062365 | 0.80 | HTR7 (0.47) | HTR7MCL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL16137958 | 0.79 | HDAC6 (0.53) | FPR2MCL1HDAC6KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| EP-4221756-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2023-08-09 | — | — | EP | disclosed |
| CN-116249554-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2022069520-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | HTR7 3905/4885FPR2 3422/4885MCL1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.